论文部分内容阅读
对各种群体的研究表明,血管紧张素转换酶抑制剂(ACEI)可以降低心血管疾病风险。ACEI的这种作用是否可以推广到所有血管疾病患者,目前还不清楚。因此,研究者对糖尿病和心血管疾病行动(ADVANCE)、欧洲培哚普利治疗稳定性冠状动脉疾病降低心脏事件研究(EUROPA)和培哚普利预防脑卒
Studies in various populations have shown that angiotensin-converting enzyme inhibitors (ACEIs) reduce the risk of cardiovascular disease. Whether this effect of ACEI can be extended to all patients with vascular diseases is unclear. Therefore, the researchers on the Diabetes and Cardiovascular Disease Action (ADVANCE), the European perindopril treatment of coronary heart disease to reduce cardiac events (EUROPA) and perindopril to prevent stroke